Table 2.
Perceptions of respondents on COVID-19 and correlation with attitude toward participation in COVID-19 clinical trials.
| Do you agree with the following statements? (Yes/no) | No. of “yes” respondents of the total sample (%) (N = 1,576) | Attitude toward participating in a clinical trial | Rho (P-value) | P-value* | |
|---|---|---|---|---|---|
| Positive (%) (n = 909) | Negative (%) (n = 667) | ||||
| The goal of conducting a clinical trial on a vaccine or drug against COVID-19 is to determine its safety and efficacy in humans. | 1,464 (93.4) | 859 (94.8) | 605 (91.4) | 0.06 (0.02) ** | 0.01 |
| Before conducting a clinical trial on either a drug or a vaccine for COVID-19, its safety and effectiveness should first be tested in animals to ensure their safety in humans. | 1,352 (86.3) | 784 (86.8) | 568 (85.7) | −0.01 (0.71) | 0.51 |
| When a vaccine for COVID-19 becomes available, I will not take it unless I am sure it is effective. | 969 (61.9) | 524 (57.8) | 445 (67.5) | 0.16 (<0.001) | <0.001 |
| When a drug for COVID-19 becomes available, I will not take it unless I am sure it is effective. | 925 (59.1) | 493 (54.5) | 432 (65.5) | –0.15 (<0.001) | <0.001 |
| Participating in a clinical trial on a vaccine for COVID-19 will increase my risk of contracting it. | 447 (28.5) | 217 (24.0) | 230 (34.7) | –0.14 (<0.001) | <0.001 |
| I am worried that I will contract COVID-19. | 978 (62.3) | 564 (62.2) | 414 (62.4) | −0.003 (0.31) | 0.92 |
| I am worried a family member (s) would contract COVID-19. | 1,340 (85.6) | 779 (86.0) | 561 (85.0) | −0.02 (0.43) | 0.59 |
| A newly developed vaccine or drug for COVID-19 will be exploited commercially. | 1,017 (65.0) | 567 (62.7) | 450 (68.2) | –0.08 (0.001) | 0.02 |
| A newly developed vaccine or drug for COVID-19 will be exploited politically. | 983 (62.8) | 559 (61.6) | 424 (64.4) | –0.05 (0.04) | 0.26 |
| Once a treatment for COVID-19 is made available, it will be affordable for most. | 647 (41.3) | 409 (45.1) | 238 (36.1) | 0.08 (0.002) | <0.001 |
| Once a vaccine for COVID-19 is made available, it will be affordable for most. | 627 (40.0) | 392 (43.2) | 235 (35.7) | 0.08 (0.001) | 0.003 |
| Interest in COVID-19 is exaggerated in general. | 563 (35.9) | 318 (35.1) | 245 (37.1) | −0.01 (0.60) | 0.40 |
| Contracting COVID-19 is closely linked to death. | 144 (9.2) | 90 (9.9) | 54 (8.2) | 0.05 (0.03) | 0.23 |
*
P-value is based on Chi-square test.
**
Bold values indicate significant P values (< 0.05).